Global Wealth Management Investment Advisory Inc. Buys 1,734 Shares of Johnson & Johnson (NYSE:JNJ)

Global Wealth Management Investment Advisory Inc. lifted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.1% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 35,691 shares of the company's stock after buying an additional 1,734 shares during the quarter. Johnson & Johnson makes up about 1.2% of Global Wealth Management Investment Advisory Inc.'s investment portfolio, making the stock its 22nd largest position. Global Wealth Management Investment Advisory Inc.'s holdings in Johnson & Johnson were worth $5,919,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in the company. Lantz Financial LLC lifted its holdings in shares of Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after purchasing an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. acquired a new stake in Johnson & Johnson during the fourth quarter worth about $453,000. Horan Securities Inc. lifted its stake in shares of Johnson & Johnson by 1.3% in the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock valued at $1,038,000 after purchasing an additional 90 shares during the period. State of Wyoming grew its position in shares of Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after acquiring an additional 10,279 shares during the period. Finally, Joel Isaacson & Co. LLC raised its position in Johnson & Johnson by 3.5% during the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after acquiring an additional 2,526 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.5%

JNJ stock traded down $0.78 during mid-day trading on Monday, reaching $155.23. 6,263,851 shares of the stock traded hands, compared to its average volume of 8,052,623. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The stock's fifty day moving average is $153.68 and its 200-day moving average is $154.17. The company has a market cap of $373.49 billion, a P/E ratio of 17.27, a P/E/G ratio of 2.36 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.35%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's payout ratio is currently 57.84%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on JNJ shares. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 5th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Barclays decreased their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Finally, The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.